GlassScriptPhysician profile
Olivia Russell
NPI 1578290201
$2,612.78
in general payments reported to CMS, 2019-2025
27 companies · $481 in 2025
The $481 reported for 2025 was more than what 78% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $146 · 2023: $1,203 · 2024: $783 · 2025: $481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,467.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,467.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $309.10 | 2022-2025 | Mounjaro, Jardiance |
| Viiv Healthcare Company | $305.74 | 2023-2024 | Apretude |
| Abbvie INC. | $240.80 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $238.56 | 2023-2025 | |
| Corium, LLC | $167.76 | 2023-2024 | Azstarys |
| Glaxosmithkline, LLC. | $165.38 | 2022-2024 | Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $162.00 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Tris Pharma INC | $113.36 | 2022-2025 | Quillivant, Dyanavel Xr, Quillichew Er |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $107.50 | 2023-2025 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $102.92 | 2023 | Xarelto |
| Dexcom, INC. | $85.17 | 2024 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $77.76 | 2023-2024 | Rexulti |
| Inspire Medical Systems, INC. | $74.49 | 2025 | Inspire |
| Amgen INC. | $51.65 | 2023-2024 | Otezla, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $47.98 | 2023 | Trintellix |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $47.70 | 2023-2025 | Contrave, Onzetra Xsail |
| Phathom Pharmaceuticals, INC. | $45.15 | 2024 | Voquezna |
| Halozyme INC | $40.74 | 2023 | |
| Esperion Therapeutics, INC. | $37.02 | 2024 | Nexletol |
| Antares Pharma, INC. | $36.95 | 2024-2025 | Xyosted |
| Idorsia Pharmaceuticals US INC | $30.27 | 2022-2023 | Quviviq |
| Astrazeneca Pharmaceuticals LP | $28.02 | 2024-2025 | Airsupra |
| Tolmar, INC. | $25.95 | 2023 | |
| Ironwood Pharmaceuticals, INC | $21.84 | 2024 | |
| Noven Therapeutics, LLC | $20.94 | 2024 | Xelstrym |
| Pfizer INC. | $14.50 | 2024 | |
| Almatica Pharma LLC | $13.53 | 2025 | Loreev Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olivia Russell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.